Current Female Contraception & Hormonal Side EffectsAssessing the Impact of Hormonal Contraceptive Use on Heavy Menstrual Bleeding

Background

Contraceptive methods are well-established in their ability to prevent pregnancy and increase individual agency in childbearing. Evidence suggests that contraceptives can also be used to treat adverse conditions associated with menstruation, including abnormal and prolonged uterine bleeding, heavy menstrual bleeding, painful menstruation, endometriosis, uterine fibroids, and premenstrual dysphoric disorders.

This review investigates the effects of contraceptive techniques such as contraceptive pills, and long-acting reversible contraceptives (e.g. intrauterine devices, implants) on menstrual morbidity.

Methods

Over ten databases with no geographical boundaries were searched from inception until October 2023. Study designs were one of the following types to be included: parallel or cluster randomised controlled trials, controlled clinical trials, controlled before and after studies, interrupted time series studies, cohort or longitudinal analyses, regression discontinuity designs, and case-control studies. Ten team members screened the papers in pairs with a Kappa score of more than 7, and Covidence was used. Conflicts were resolved by discussion, and the full papers were divided among the reviewers to extract the data from eligible studies.

Results

Hormonal contraceptives are considered a well-tolerated, non-invasive, and clinically effective treatment for abnormal and prolonged uterine bleeding, heavy menstrual bleeding, painful menstruation, endometriosis, uterine fibroids, and premenstrual dysphoric disorders. Our studies investigating quality of life or well-being in women with heavy menstrual bleeding, endometriosis, or uterine fibroids have found improvements in all dimensions assessed.

Conclusions

Hormonal contraceptives significantly reduce pain, symptom severity, and abnormal bleeding patterns associated with women who suffer from heavy menstrual bleeding, endometriosis, and uterine fibroids.

Link:

Related articles

Journal :

JAMA (Feb 2025) · 2025

This work assesses VTE risk among modern hormonal contraceptives, showing that estrogen dose and progestin choice meaningfully influence the absolute and relative VTE risk.

Journal :

The BMJ (Jan 2025) · 2025

Registry analysis: slight increased risk of meningioma after >5 years continuous use of desogestrel 75 µg; no risk signal for levonorgestrel.

Journal :

The BMJ (Mar 2024) · 2024

French nationwide data: prolonged use of certain high-dose progestogens is associated with increased intracranial meningioma risk; no increased risk observed with levonorgestrel IUD.

Drag